Beijing Innocare Pharma Tech Co., Ltd.

This early-stage trial tests an experimental drug called ICP-248, taken as a pill, for people with B-cell blood cancers like leukemia and lymphoma. The study will see if the drug is safe, what dose works best, and whether it helps shrink tumors. About 191 adults aged 18 to 80 are…

This Phase 3 trial tests an oral drug called ICP-488 in 383 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either the drug or a placebo for 16 weeks. The main goal is to see if the drug can significantly clear or nearly clear the sk…

This study tests a new medication called ICP-332 for people with moderate to severe chronic spontaneous urticaria (hives) that aren't controlled by standard antihistamines. About 344 adults will receive either the drug or a placebo for up to 24 weeks. The main goal is to see if i…

This study tests a new drug combination (ICP-248 plus orelabrutinib) in people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if the combination is safe and tolerable. About 226 adults aged 18 to 80 with measurable disease and a need…

This phase 3 trial compares two drug combinations for adults with marginal zone lymphoma that has returned or not responded to prior treatment. Participants will receive either orelabrutinib plus rituximab or lenalidomide plus rituximab. The goal is to see which combo works bette…

This study tests an oral medication called ICP-332 for adults with moderate to severe atopic dermatitis (eczema). About 552 participants will receive either the drug or a placebo daily for several weeks. The main goal is to see if the drug significantly reduces skin redness, itch…

This study tests an experimental drug called ICP-723 in adults and teenagers with advanced solid tumors that cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 310 participants will take part i…

This study tests an experimental drug called ICP-248 in 75 adults whose mantle cell lymphoma has returned or stopped responding to prior therapy. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also monitor side effects and how long any ben…

This study tests an experimental drug called ICP-332 against a placebo in 172 adults with moderate-to-severe plaque psoriasis. The main goal is to see if more people achieve a 75% improvement in their psoriasis symptoms after 12 weeks of treatment. Participants must have had psor…

This study tests an experimental drug called ICP-723 in people whose advanced solid tumors or brain tumors have a specific genetic change called NTRK fusion. About 70 participants will receive the drug to see if it shrinks tumors or slows their growth. The goal is to find a new t…

This early-phase study tests a new drug (ICP-248) combined with a standard medicine (azacitidine) in people with acute myeloid leukemia or myelodysplastic syndromes. The goal is to find a safe dose and see if the combo helps control the disease. About 266 adults who have not resp…

This study tests an experimental drug called ICP-332 for people with prurigo nodularis, a skin condition causing many intensely itchy bumps. About 135 adults will receive either the drug or a placebo to see if it reduces itching and clears the bumps over 16 weeks. The goal is to …

This early-phase trial is testing the safety and tolerability of a new drug called ICP-538 in 104 healthy adults. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and how the drug moves through the body. The goal is to gather b…